Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Share:
Related AGN
Valeant CEO On Allegations Against The Company And Future M&A Deals
What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts
Sientra: A Breast Implant Pure-Play With A Technologically Superior Implant, Initiating Bullish (Seeking Alpha)
Related VRX
UPDATE: Morgan Stanley Reiterates, Raises Price Target On Valeant Pharmaceuticals As Jublia Formulary Concerns Are Noise
Valeant CEO On Allegations Against The Company And Future M&A Deals
Seeking Alpha's Biotech Weekly: Intercept Pops, Provenge's Prince Valeant, And More (Seeking Alpha)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General

 

Related Articles (AGN + VRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters